Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high‐risk prostate cancer

Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Over‐treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate...

Full description

Saved in:
Bibliographic Details
Published inBJU international Vol. 110; no. 11b; pp. E783 - E788
Main Authors Yerram, Nitin K., Volkin, Dmitry, Turkbey, Baris, Nix, Jeffrey, Hoang, Anthony N., Vourganti, Srinivas, Gupta, Gopal N., Linehan, W. Marston, Choyke, Peter L., Wood, Bradford J., Pinto, Peter A.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.12.2012
Subjects
Online AccessGet full text
ISSN1464-4096
1464-410X
1464-410X
DOI10.1111/j.1464-410X.2012.11646.x

Cover

Abstract Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Over‐treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. Objective To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low‐risk cancers that often lead to overtreatment. Patients and Methods We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2‐weighted, diffusion‐weighted, spectroscopic and dynamic contrast‐enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. Results In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high‐risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high‐risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. Conclusions The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low‐grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high‐risk prostate cancers.
AbstractList What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer.UNLABELLEDWhat's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer.To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment.OBJECTIVETo determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment.We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis.PATIENTS AND METHODSWe reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis.In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease.RESULTSIn total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease.The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers.CONCLUSIONSThe results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers.
Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Over‐treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. Objective To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low‐risk cancers that often lead to overtreatment. Patients and Methods We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2‐weighted, diffusion‐weighted, spectroscopic and dynamic contrast‐enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. Results In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high‐risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high‐risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. Conclusions The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low‐grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high‐risk prostate cancers.
What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment. We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk (≥ Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers.
Study Type - Diagnostic (case series) Level of Evidence-4 What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human and medical costs. Lesions with a low suspician level at mpMRI of the prostate have low risk of including high risk prostate cancer. Objective To determine whether multiparametric magnetic resonance imaging (mpMRI) has the potential to identify patients at low risk for cancer, thus obviating the need for biopsy. Prostate cancer is currently diagnosed by random biopsies, resulting in the discovery of multiple low-risk cancers that often lead to overtreatment. Patients and Methods We reviewed 800 consecutive patients who underwent a 3 Tesla mpMRI of the prostate with an endorectal coil from March 2007 to November 2011. All suspicious lesions were independently reviewed by two radiologists using T2-weighted, diffusion-weighted, spectroscopic and dynamic contrast-enhanced MRI sequences. Patients with only low suspicion lesions (maximum of two positive parameters on mpMRI) who subsequently underwent transrectal ultrasonography (TRUS)/MRI fusion targeted biopsy were selected for analysis. Results In total, 125 patients with only low suspicion prostatic lesions on mpMRI were identified. On TRUS/MRI fusion biopsy, 77 (62%) of these patients had no cancer detected, 38 patients had Gleason 6 disease and 10 patients had Gleason 7 (3+4) disease. There were 30 patients with cancer detected on biopsy who qualified for active surveillance using 2011 National Comprehensive Cancer Network guidelines. No cases of high-risk ( Gleason 4+3) cancer were identified on biopsy and, of the fifteen patients who underwent radical prostatectomy at our institution, none were pathologically upgraded to high-risk cancer. Thus, for patients with only low suspicion lesions, 107 (88%) patients either had no cancer or clinically insignificant disease. Conclusions The results obtained in the present study show that low suspicion lesions on mpMRI are associated with either negative biopsies or low-grade tumours suitable for active surveillance. Such patients have a low risk of harbouring high-risk prostate cancers [PUBLICATION ABSTRACT].
Author Pinto, Peter A.
Wood, Bradford J.
Yerram, Nitin K.
Hoang, Anthony N.
Choyke, Peter L.
Volkin, Dmitry
Vourganti, Srinivas
Gupta, Gopal N.
Linehan, W. Marston
Nix, Jeffrey
Turkbey, Baris
AuthorAffiliation 2 Center for Interventional Oncology, Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda MD
3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda MD
1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD
AuthorAffiliation_xml – name: 3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda MD
– name: 1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD
– name: 2 Center for Interventional Oncology, Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda MD
Author_xml – sequence: 1
  givenname: Nitin K.
  surname: Yerram
  fullname: Yerram, Nitin K.
  organization: National Cancer Institute
– sequence: 2
  givenname: Dmitry
  surname: Volkin
  fullname: Volkin, Dmitry
  organization: National Cancer Institute
– sequence: 3
  givenname: Baris
  surname: Turkbey
  fullname: Turkbey, Baris
  organization: National Institutes of Health
– sequence: 4
  givenname: Jeffrey
  surname: Nix
  fullname: Nix, Jeffrey
  organization: National Cancer Institute
– sequence: 5
  givenname: Anthony N.
  surname: Hoang
  fullname: Hoang, Anthony N.
  organization: National Cancer Institute
– sequence: 6
  givenname: Srinivas
  surname: Vourganti
  fullname: Vourganti, Srinivas
  organization: National Cancer Institute
– sequence: 7
  givenname: Gopal N.
  surname: Gupta
  fullname: Gupta, Gopal N.
  organization: National Cancer Institute
– sequence: 8
  givenname: W. Marston
  surname: Linehan
  fullname: Linehan, W. Marston
  organization: National Cancer Institute
– sequence: 9
  givenname: Peter L.
  surname: Choyke
  fullname: Choyke, Peter L.
  organization: National Institutes of Health
– sequence: 10
  givenname: Bradford J.
  surname: Wood
  fullname: Wood, Bradford J.
  organization: Center for Interventional Oncology
– sequence: 11
  givenname: Peter A.
  surname: Pinto
  fullname: Pinto, Peter A.
  organization: Center for Interventional Oncology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23130821$$D View this record in MEDLINE/PubMed
BookMark eNqVUsuOEzEQtNAi9gG_gCxx4ZLgx9iZuSDBChZQJC6stDfLY_ckDhN7sGdIwmk_gW_kS_BsdsNDAoEv3eruKleXfYqOfPCAEKZkSvN5tprSQhaTgpKrKSOU5aos5HR7D50cGkd3OankMTpNaUVILkjxAB0zTjkpGT1BX-Zhg9OQOmdc8LiFlEPCOV0Pbe86HfUa-ugMXuuFhz4nEVLw2hvALtecX-AugnWmx02IuF8C1nWCsR8avHSL5bfrr9Glj3kspF73gM2Ijg_R_Ua3CR7dxjN0-frVh_M3k_n7i7fnL-YTIwiXk5JXjTCEaialBcJZ1cxqY-uiFpJBLWvLiJgJXklhZ9yKmTWW8VpaQUXZWMnPULXnHXyndxvdtqqLWXrcKUrU6KdaqdEqlW3bqtFPdeOn2mbs8z22G-o1WAO-j_oHPminfu14t1SL8FnxkpRUkkzw9JYghk8DpF6tXTLQttpDGJKinArJJeOjzie_ja7CEH22JqsjkhHGypHw8c-KDlLunjQPlPsBk-1OEZq_bHv1h20PUOPyg-UfkXdz7X8QbFwLu3--WL18d3mT8u9aZuAG
CODEN BJINFO
CitedBy_id crossref_primary_10_1007_s11547_017_0803_1
crossref_primary_10_1186_s43055_022_00755_7
crossref_primary_10_1111_bju_14049
crossref_primary_10_1371_journal_pone_0157313
crossref_primary_10_1111_bju_13711
crossref_primary_10_1007_s00330_016_4635_5
crossref_primary_10_1038_pcan_2017_34
crossref_primary_10_1056_NEJMoa1910038
crossref_primary_10_1097_RMR_0000000000000081
crossref_primary_10_3349_ymj_2017_58_5_994
crossref_primary_10_1186_s12885_019_6434_2
crossref_primary_10_1016_j_urology_2014_03_012
crossref_primary_10_1016_j_urolonc_2016_02_020
crossref_primary_10_12677_ACM_2023_133698
crossref_primary_10_1155_2014_590638
crossref_primary_10_1245_s10434_016_5438_2
crossref_primary_10_1016_j_ejrad_2014_06_026
crossref_primary_10_1080_13685538_2019_1641796
crossref_primary_10_1097_RCT_0000000000000172
crossref_primary_10_3389_fonc_2023_1102860
crossref_primary_10_1007_s00259_013_2419_6
crossref_primary_10_2214_AJR_13_11061
crossref_primary_10_2214_AJR_15_15768
crossref_primary_10_1002_jmri_25641
crossref_primary_10_2214_AJR_16_16843
crossref_primary_10_1093_jnci_djw039
crossref_primary_10_1097_MOU_0000000000000047
crossref_primary_10_1016_j_brachy_2014_01_011
crossref_primary_10_1590_s1677_5538_ibju_2016_0511
crossref_primary_10_62347_JHYY2053
crossref_primary_10_1002_jmri_24983
crossref_primary_10_1007_s11255_017_1715_7
crossref_primary_10_1007_s11255_017_1670_3
crossref_primary_10_1007_s13244_016_0466_9
crossref_primary_10_1038_aja_2013_39
crossref_primary_10_1007_s11934_015_0507_9
crossref_primary_10_1007_s11934_013_0387_9
crossref_primary_10_1159_000441733
crossref_primary_10_1016_j_urolonc_2021_01_008
crossref_primary_10_1002_cncr_28216
crossref_primary_10_1038_nrclinonc_2014_44
crossref_primary_10_1038_pcan_2017_21
crossref_primary_10_1155_2014_203906
crossref_primary_10_1016_j_acra_2015_02_006
crossref_primary_10_1016_j_juro_2017_02_073
crossref_primary_10_1016_j_pnmrs_2018_01_001
crossref_primary_10_1016_j_ejrad_2017_08_017
crossref_primary_10_1016_j_urology_2016_04_037
crossref_primary_10_1093_jnci_djw040
crossref_primary_10_1111_bju_12639
crossref_primary_10_1016_j_urology_2017_02_027
crossref_primary_10_1007_s00120_012_3096_y
crossref_primary_10_1002_pros_24435
crossref_primary_10_1007_s11548_020_02172_5
crossref_primary_10_1016_j_juro_2013_05_118
crossref_primary_10_1111_bju_12335
crossref_primary_10_1007_s00261_017_1135_2
crossref_primary_10_1038_nrurol_2016_26
crossref_primary_10_1097_MD_0000000000011962
crossref_primary_10_1016_j_urology_2016_10_040
crossref_primary_10_1038_s41585_022_00587_0
crossref_primary_10_1016_j_ejrad_2016_11_016
crossref_primary_10_1016_j_euo_2019_08_001
crossref_primary_10_1016_j_juro_2014_10_122
crossref_primary_10_1111_iju_12259
crossref_primary_10_3389_fonc_2023_1092073
crossref_primary_10_1007_s00120_014_3440_5
crossref_primary_10_1007_s11255_016_1212_4
crossref_primary_10_1111_bju_13619
Cites_doi 10.1016/j.eururo.2010.09.003
10.1016/S0022-5347(01)65201-7
10.3109/10929080802364645
10.1097/01.ju.0000158155.33890.e7
10.1016/j.juro.2011.05.078
10.3322/caac.20073
10.1200/JCO.2003.01.075
10.1016/j.urolonc.2010.08.023
10.1007/s00330-011-2377-y
10.1200/JCO.2010.31.4252
10.1016/j.juro.2010.12.033
10.1002/cncr.22262
10.1038/nrclinonc.2009.18
10.1016/j.juro.2010.10.076
10.1148/radiol.2392050949
10.1016/j.juro.2011.07.013
10.1148/radiol.10100667
10.1016/j.urology.2010.05.044
10.1016/j.juro.2007.07.043
10.1016/j.eururo.2011.08.042
10.1016/j.juro.2007.07.049
ContentType Journal Article
Copyright 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS
2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS.
BJUI Copyright 2012 BJU International
Copyright_xml – notice: 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS
– notice: 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS.
– notice: BJUI Copyright 2012 BJU International
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7X8
5PM
ADTOC
UNPAY
DOI 10.1111/j.1464-410X.2012.11646.x
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Calcium & Calcified Tissue Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1464-410X
EndPage E788
ExternalDocumentID 10.1111/j.1464-410x.2012.11646.x
PMC3808160
3024933221
23130821
10_1111_j_1464_410X_2012_11646_x
BJU11646
Genre article
Journal Article
Comparative Study
Research Support, N.I.H., Intramural
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: Z01 BC011089
– fundername: Intramural NIH HHS
  grantid: ZIA BC011081
– fundername: Intramural NIH HHS
  grantid: ZIE BC011023
– fundername: Division of Basic Sciences : NCI
  grantid: ZIE BC011023-05 || BC
– fundername: Division of Basic Sciences : NCI
  grantid: Z01 BC011089-01 || BC
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OB
1OC
23N
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIDQK
AIDYY
AIQQE
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
~IA
~WT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c5036-839f5c01a266de0329f7bcdb4b562eb6bd205753965d73d57dcd23b6d5158fd63
IEDL.DBID UNPAY
ISSN 1464-4096
1464-410X
IngestDate Sun Oct 26 02:58:22 EDT 2025
Tue Sep 30 15:46:53 EDT 2025
Thu Oct 02 13:58:07 EDT 2025
Tue Oct 07 06:28:02 EDT 2025
Mon Jul 21 05:29:11 EDT 2025
Wed Oct 01 04:28:58 EDT 2025
Thu Apr 24 22:54:13 EDT 2025
Fri Sep 19 01:20:14 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11b
Language English
License 2012 BJU INTERNATIONAL; NO CLAIM TO ORIGINAL US GOVERNMENT WORKS.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5036-839f5c01a266de0329f7bcdb4b562eb6bd205753965d73d57dcd23b6d5158fd63
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2012.11646.x
PMID 23130821
PQID 1406202280
PQPubID 1026371
ParticipantIDs unpaywall_primary_10_1111_j_1464_410x_2012_11646_x
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3808160
proquest_miscellaneous_1315636236
proquest_journals_1406202280
pubmed_primary_23130821
crossref_primary_10_1111_j_1464_410X_2012_11646_x
crossref_citationtrail_10_1111_j_1464_410X_2012_11646_x
wiley_primary_10_1111_j_1464_410X_2012_11646_x_BJU11646
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2012
PublicationDateYYYYMMDD 2012-12-01
PublicationDate_xml – month: 12
  year: 2012
  text: December 2012
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Edgecliff
PublicationTitle BJU international
PublicationTitleAlternate BJU Int
PublicationYear 2012
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2012; 61
1997; 157
2011; 258
2007; 178
2005; 173
2010; 58
2010; 29
2011; 77
2008; 13
2009; 6
2011; 185
2007; 10
2006; 239
2006; 107
2012; 22
2003; 21
2012; 30
2010; 60
2011; 186
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_2_1
Xu S (e_1_2_7_8_1) 2007; 10
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_23_1
e_1_2_7_11_1
e_1_2_7_22_1
e_1_2_7_10_1
e_1_2_7_21_1
e_1_2_7_20_1
References_xml – volume: 30
  start-page: 301
  year: 2012
  end-page: 305
  article-title: Endorectal T2‐weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance
  publication-title: Urol Oncol
– volume: 13
  start-page: 255
  year: 2008
  end-page: 264
  article-title: Real‐time MRI‐TRUS fusion for guidance of targeted prostate biopsies
  publication-title: Comput Aided Surg
– volume: 157
  start-page: 559
  year: 1997
  end-page: 562
  article-title: Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications
  publication-title: J Urol
– volume: 58
  start-page: 836
  year: 2010
  end-page: 837
  article-title: Further support for active surveillance in the management of low‐volume, low‐grade prostate cancer
  publication-title: Eur Urol
– volume: 107
  start-page: 2384
  year: 2006
  end-page: 2391
  article-title: Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy
  publication-title: Cancer
– volume: 29
  start-page: 228
  year: 2010
  end-page: 234
  article-title: Outcomes of active surveillance for men with intermediate‐risk prostate cancer
  publication-title: J Clin Oncol
– volume: 22
  start-page: 746
  year: 2012
  end-page: 757
  article-title: ESUR prostate MR guidelines 2012
  publication-title: Eur Radiol
– volume: 77
  start-page: 422
  year: 2011
  end-page: 426
  article-title: Estimation of prostate size in community‐dwelling men
  publication-title: Urology
– volume: 186
  start-page: 1818
  year: 2011
  end-page: 1824
  article-title: Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds
  publication-title: J Urol
– volume: 186
  start-page: 1281
  year: 2011
  end-page: 1285
  article-title: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging
  publication-title: J Urol
– volume: 185
  start-page: 1645
  year: 2011
  end-page: 1649
  article-title: Overuse of imaging for staging low risk prostate cancer
  publication-title: J Urol
– volume: 178
  start-page: 1925
  year: 2007
  end-page: 1928
  article-title: Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer
  publication-title: J Urol
– volume: 10
  start-page: 128
  year: 2007
  end-page: 135
  article-title: Closed‐loop control in fused MR‐TRUS image‐guided prostate biopsy
  publication-title: Med Image Comput Comput Assist Interv
– volume: 185
  start-page: 815
  year: 2011
  end-page: 820
  article-title: D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging
  publication-title: J Urol
– volume: 173
  start-page: 1938
  year: 2005
  end-page: 1942
  article-title: The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy
  publication-title: J Urol
– volume: 60
  start-page: 277
  year: 2010
  end-page: 300
  article-title: Cancer statistics, 2010
  publication-title: CA Cancer J Clin
– volume: 178
  start-page: 1957
  year: 2007
  end-page: 1962
  article-title: Validity of the CAPRA score to predict biochemical recurrence‐free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients
  publication-title: J Urol
– volume: 239
  start-page: 784
  year: 2006
  end-page: 792
  article-title: Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging
  publication-title: Radiology
– volume: 258
  start-page: 488
  year: 2011
  end-page: 495
  article-title: Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3‐T MR images?
  publication-title: Radiology
– volume: 61
  start-page: 177
  year: 2012
  end-page: 184
  article-title: Prospective assessment of prostate cancer aggressiveness using 3‐T diffusion‐weighted magnetic resonance imaging‐guided biopsies versus a systematic 10‐core transrectal ultrasound prostate biopsy cohort
  publication-title: Eur Urol
– volume: 6
  start-page: 197
  year: 2009
  end-page: 206
  article-title: Is it time to consider a role for MRI before prostate biopsy?
  publication-title: Nat Rev Clin Oncol
– volume: 21
  start-page: 2163
  year: 2003
  end-page: 2172
  article-title: Cancer‐specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate‐specific antigen era
  publication-title: J Clin Oncol
– ident: e_1_2_7_11_1
  doi: 10.1016/j.eururo.2010.09.003
– ident: e_1_2_7_19_1
  doi: 10.1016/S0022-5347(01)65201-7
– ident: e_1_2_7_9_1
  doi: 10.3109/10929080802364645
– ident: e_1_2_7_17_1
  doi: 10.1097/01.ju.0000158155.33890.e7
– ident: e_1_2_7_4_1
  doi: 10.1016/j.juro.2011.05.078
– ident: e_1_2_7_2_1
  doi: 10.3322/caac.20073
– ident: e_1_2_7_13_1
  doi: 10.1200/JCO.2003.01.075
– ident: e_1_2_7_20_1
  doi: 10.1016/j.urolonc.2010.08.023
– ident: e_1_2_7_23_1
  doi: 10.1007/s00330-011-2377-y
– ident: e_1_2_7_14_1
  doi: 10.1200/JCO.2010.31.4252
– ident: e_1_2_7_21_1
  doi: 10.1016/j.juro.2010.12.033
– ident: e_1_2_7_16_1
  doi: 10.1002/cncr.22262
– ident: e_1_2_7_10_1
  doi: 10.1038/nrclinonc.2009.18
– ident: e_1_2_7_5_1
  doi: 10.1016/j.juro.2010.10.076
– ident: e_1_2_7_7_1
  doi: 10.1148/radiol.2392050949
– ident: e_1_2_7_3_1
  doi: 10.1016/j.juro.2011.07.013
– ident: e_1_2_7_22_1
  doi: 10.1148/radiol.10100667
– volume: 10
  start-page: 128
  year: 2007
  ident: e_1_2_7_8_1
  article-title: Closed‐loop control in fused MR‐TRUS image‐guided prostate biopsy
  publication-title: Med Image Comput Comput Assist Interv
– ident: e_1_2_7_12_1
  doi: 10.1016/j.urology.2010.05.044
– ident: e_1_2_7_15_1
  doi: 10.1016/j.juro.2007.07.043
– ident: e_1_2_7_6_1
  doi: 10.1016/j.eururo.2011.08.042
– ident: e_1_2_7_18_1
  doi: 10.1016/j.juro.2007.07.049
SSID ssj0014665
Score 2.3713872
Snippet Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Over‐treatment of indolent prostate cancer...
What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer lesions is a problem which can result in increased human...
Study Type - Diagnostic (case series) Level of Evidence-4 What's known on the subject? and What does the study add? Over-treatment of indolent prostate cancer...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage E783
SubjectTerms active surveillance
Adult
Aged
Aged, 80 and over
Biopsy
Humans
low suspicion lesion
Magnetic Resonance Imaging - methods
Male
Middle Aged
Neoplasm Staging - methods
NMR
Nuclear magnetic resonance
Predictive Value of Tests
Prospective Studies
Prostate - pathology
Prostate cancer
prostate MRI
Prostatic Neoplasms - diagnosis
Reproducibility of Results
Risk Factors
SummonAdditionalLinks – databaseName: Wiley Online Library - Core collection (SURFmarket)
  dbid: DR2
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hHkovUCjQlIIWiasj2_twfAREVUWUAyJSbta-XKqmdhTHSuipP4HfyC9hZu1YclqhCHHzY8b2rGd2v7VnvyHkPYBopTn0fs45GXAYQyGkhA6YTEcmN7HIQ1wofPFVnk_4eCqmbf4TroVp-CG6D24YGb6_xgBXutoOch7wKJxihlYMxyWXQ8STEZN-dvWtY5ICUV9VslEB2N5P6nnwQv2R6h78vJ9F-bgu5urnSs1mfaTrh6qzp-R6Y2SToXI9rJd6aG63-B__TysckictoqUfGhd8Rh654jnZv2j_2R-R2y_lilZ1NYf9sqAzh9_nKgqbTTKjwvQwrBNAb9RlgWsq6cLhBAHckV7d-CpKdL7A6y0pQGwKkJXC42GXRMucIuHy77tfmCMPYqVfIUUNai9ekMnZ5--fzoO24kNghGdGZmkuTBgpgA3WhSxO80Qbq7kGmOa01DZGfMlSKWzCrEissTHT0gIqG-VWspdkrygLd0yotDLSMNcNjXCcKaHkKDIa_NKkyKDvBiTZvN3MtHToWJVjlvWmRTzDps2waTPftNl6QKJOc95Qguygc7pxoKztJCoQDWXs-YgG5F13GsIb_9mowpU1yDCYYAPIYHJAXjX-1t0UoDmSDUVgSs8TOwGkDu-fKa5-eApx5guuwH3jzmf_Yst6y5bEe-TOxmcfxxO_efLPmq_JAR5v8ohOyd5yUbs3gAaX-q2P8z-16FHJ
  priority: 102
  providerName: Wiley-Blackwell
Title Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high‐risk prostate cancer
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2012.11646.x
https://www.ncbi.nlm.nih.gov/pubmed/23130821
https://www.proquest.com/docview/1406202280
https://www.proquest.com/docview/1315636236
https://pubmed.ncbi.nlm.nih.gov/PMC3808160
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-410X.2012.11646.x
UnpaywallVersion publishedVersion
Volume 110
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1464-410X
  dateEnd: 20241101
  omitProxy: true
  ssIdentifier: ssj0014665
  issn: 1464-410X
  databaseCode: ABDBF
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1464-410X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014665
  issn: 1464-410X
  databaseCode: DIK
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1464-410X
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1464-410X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0014665
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqrQRceD8WSmUkrlmS-JHNsSCqqqIrhFhpOUV-hVZsk2izUZee-An8Rn4JM042Iq2EKsTNScaxxhnb3zgznwl5DSBaaQ6zn3NOBhzWUBhSQgdMplOTm1jkISYKn8zk0ZwfL8Rih8y2uTAtP0S_4YYjw8_XOMArm7fz_Js_4nG45AGPwgVGacVwV3I5AUy5KwVg8xHZnc8-HnxpU4xAMExlX4ZKw9Ce7u5m8KrhenUNhF6PpbzdFJX6fqGWyyHe9QvW4T1SblVt41S-TZq1npjLKyyQ_68v7pO7HbalB60xPiA7rnhIbp10f-8fkcsP5QWtm7qC67KgS4c7dTWFYhvWqDBQDE8MoOfqa4HZlXTl0FUAw6Rn5_48JVqt8H1rCmCbAnilStc4OdEyp0i9_OvHT4yWB7HS50pRg7VXj8n88P3nd0dBd_ZDYITnSGZpLkwYKQAQ1oUsTvNEG6u5BsDmtNQ2RqTJUilswqxIrLEx09ICPpvmVrInZFSUhXtGqLQy0uD1hkY4zpRQchoZDRZqUuTSd2OSbL9wZjpidDyfY5kNHCSeYddm2LWZ79psMyZRX7NqyUFuUGdva0RZN13UIBrK2DMTjcmr_jEMdPx7owpXNiDDwNUGuMHkmDxtba5vFEA60g5FoMrAGnsBJBEfPinOTj2ZOPNHr0C7cW-3f9Flc0WXxFvljZXP3h7PffH5vzT3gtzByzaYaI-M1qvGvQRIuNb74Ax9ive70f4bfV5Xhw
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQkSiX8oalBYzENaskjp3NsTyqpez2gLrS3iK_UirSZLXZqI8TP6G_kV_SGScbKVuEKsQtj5lE48zYn53xN4R8ABAtVQS9n7VWeBGMoRBSXHlMJCOd6ZBnPm4Unh6J8Sw6nPN5Ww4I98I0_BDdghtGhuuvMcBxQXozyiMvCvw5pmiFcF1EYgiA8j5c99HFP3_vuKRA1tWVbHQAuPfTev74pP5YdQuA3s6j3K6Lhbw8l3nex7pusDp4RPK1mU2Oys9hvVJDfbXBAPmf2uEx2WlBLd1vvPAJuWeLp-TBtP1t_4xcTcpzWtXVAs7LguYWl-gqCodNPqPEDDEsFUDP5EmB2yrp0uIcATySnp65Qkp0scTnrSigbAqolUpVYa9Ey4wi5_LvX9eYJg9ipdskRTVqL5-T2cGX409jry364GnuyJFZknHtBxKQg7E-C5MsVtqoSAFSs0ooEyLEZIngJmaGx0abkClhAJiNMiPYC7JVlIV9RagwIlAw3fU1txGTXIpRoBW4pk6QRN8OSLz-vKluGdGxMEee9mZGUYpNm2LTpq5p04sBCTrNRcMKcgedvbUHpW0_UYGoL0JHSTQg77vbEOH420YWtqxBhsEcG3AGEwPysnG47qWAzpFvKABTeq7YCSB7eP9OcfrDsYgzV3MF3ht2TvsXWy42bImdS97Z-PTj4cwdvv5nzXdke3w8naSTr0ffdslDlGnSivbI1mpZ2zcADlfqrQv6G89aVeo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQkQoXypstBYzEdVdJ_MjmCJRVKW2FECvtLfIrUJEm0Wajlp74CfxGfgkzTjZStghViFseM7HGmbE_J-NvCHkFIFppDqOfc06OOcyhEFJCj5lMpiYzkcgC3Ch8fCIP5vxwIRZdOSDcC9PyQ_Qf3DAy_HiNAe4qm21GOR_zMFhgilYE1yWXEwCUN7lIppjft_-p55ICWV9XstUB4D5M6_njk4Zz1RUAejWP8lZTVOr7ucrzIdb1k9Vsh-RrM9sclW-TZqUn5nKDAfI_9cNdcqcDtfR164X3yA1X3Cfbx91v-wfk8qg8p3VTV3BeFjR3-ImupnDY5jMqzBDDUgH0TH0pcFslXTpcI4BH0tMzX0iJVkt83ooCyqaAWqnSNY5KtMwoci7_-vET0-RBrPSbpKhB7eVDMp-9-_z2YNwVfRgb4cmRWZIJE4QKkIN1AYuSLNbGaq4BqTkttY0QYrJEChszK2JrbMS0tADMppmV7BHZKsrCPSFUWhlqWO4GRjjOlFByGhoNrmkSJNF3IxKvX29qOkZ0LMyRp4OVEU-xa1Ps2tR3bXoxImGvWbWsINfQ2Vt7UNqNEzWIBjLylEQj8rK_DRGOv21U4coGZBissQFnMDkij1uH6xsFdI58QyGYMnDFXgDZw4d3itOvnkWc-Zor0G7UO-1fbLnYsCX2Lnlt49M3h3N_uPvPmi_I9sf9WXr0_uTDU3IbRdqsoj2ytVo27hlgw5V-7mP-NwJHVW4
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqrQRceD-2FGQkrlmS-JHNsSCqqqIrDqy0nCK_AlW3SbTZqEtP_Qn8Rn4JM042Iq2EKsTNScaxxpmxPzsznwl5CyBaaQ6jn3NOBhzmUHApoQMm06nJTSzyEBOFT2byaM6PF2KxQ2bbXJiWH6LfcEPP8OM1Onhl83acf_dHPA6XPOBRuMAorRjuSi4ngCl3pQBsPiK789nng69tihEIhqnsy1BpGNrT3d0MXjWcr26A0JuxlHebolI_LtRyOcS7fsI6fEDKraptnMrZpFnribm8xgL5__riIbnfYVt60BrjI7Ljisfkzkn39_4JufxUXtC6qSu4Lgu6dLhTV1MotmGNCgPF8MQAeq6-FZhdSVcOlwpgmPT03J-nRKsVvm9NAWxTAK9U6RoHJ1rmFKmXf139xGh5ECt9rhQ1WHv1lMwPP375cBR0Zz8ERniOZJbmwoSRAgBhXcjiNE-0sZprAGxOS21jRJoslcImzIrEGhszLS3gs2luJXtGRkVZuBeESisjDave0AjHmRJKTiOjwUJNilz6bkyS7RfOTEeMjudzLLPBAoln2LUZdm3muzbbjEnU16xacpBb1NnfGlHWDRc1iIYy9sxEY_KmfwyOjn9vVOHKBmQYLLUBbjA5Js9bm-sbBZCOtEMRqDKwxl4AScSHT4rT755MnPmjV6DduLfbv-iyuaZL4q3y1spn74_nvrj3L829JPfwsg0m2iej9apxrwASrvXrzs9_A3YCVp4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+suspicion+lesions+on+multiparametric+magnetic+resonance+imaging+predict+for+the+absence+of+high-risk+prostate+cancer&rft.jtitle=BJU+international&rft.au=Yerram%2C+Nitin+K&rft.au=Volkin%2C+Dmitry&rft.au=Turkbey%2C+Baris&rft.au=Nix%2C+Jeffrey&rft.date=2012-12-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=110&rft.issue=11b&rft.spage=E783&rft_id=info:doi/10.1111%2Fj.1464-410X.2012.11646.x&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3024933221
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon